Alexion Pharmaceuticals (ALXN) raised its 2014 guidance Monday after cutting a reimbursement deal with the French government, sending the stock up 5.5% in morning trading in the stock market today. Although the company’s press release doesn’t provide much detail, Alexion said it had concluded discussions with the French government regarding reimbursement for its sole marketed drug, Soliris, as a treatment for a rare disease called atypical
With the stock market back in a confirmed uptrend, investors may want to look for big-cap companies with high Accumulation/Distributions grades that point to large institutions buying their stocks. Alexion Pharmaceuticals (ALXN), Illumina (ILMN), Micron (MU) and FleetCor Technologies (FLT) are all companies on the IBD’s Big Cap Screen of the Day that have an Accumulation/Distribution grade of A- or higher. Illumina, a maker of gene sequencing
Alexion Pharmaceuticals (ALXN) stock rocketed Thursday, after the maker of drugs for blood, neurological and other diseases late Wednesday issued Q4 earnings and sales that beat forecasts. The Cheshire, Conn.-based firm also gave a better-than-expected forecast for 2014, based on improving sales and reduced tax payments that spurred investors. Alexion stock was up 22%, near 163, in afternoon trading in the stock market today. Alexion stock ranks